Provided by Tiger Fintech (Singapore) Pte. Ltd.

Supernus Pharmaceuticals

33.20
+0.15000.45%
Post-market: 33.200.00000.00%16:26 EDT
Volume:488.74K
Turnover:16.22M
Market Cap:1.86B
PE:29.99
High:33.49
Open:32.98
Low:32.83
Close:33.05
Loading ...

Does The Market Have A Low Tolerance For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Fundamentals?

Simply Wall St.
·
03 Mar

Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stocks to Buy Now?

Insider Monkey
·
03 Mar

Supernus Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
27 Feb

Q4 2024 Supernus Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
27 Feb

Supernus Pharmaceuticals Price Target Maintained With a $36.00/Share by Cantor Fitzgerald

Dow Jones
·
26 Feb

Stifel Nicolaus Remains a Hold on Supernus Pharmaceuticals (SUPN)

TIPRANKS
·
26 Feb

Supernus Pharmaceuticals Q4 Earnings, Revenue Rise; Provides 2025 Revenue Guidance

MT Newswires Live
·
26 Feb

Supernus Pharmaceuticals Inc (SUPN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...

GuruFocus.com
·
26 Feb

Supernus Pharmaceuticals Reports Strong 2024 Financial Growth

TIPRANKS
·
26 Feb

Supernus Pharmaceuticals: Strong Buy Rating Backed by Qelbree’s Growth and Promising Revenue Outlook

TIPRANKS
·
26 Feb

Supernus (SUPN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks
·
26 Feb

Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates

Zacks
·
26 Feb

Supernus Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
26 Feb

Supernus: Q4 Earnings Snapshot

Associated Press Finance
·
26 Feb

Supernus Pharmaceuticals Q4 EPS $0.27 Misses $0.52 Estimate, Sales $174.16M Beat $155.25M Estimate

Benzinga
·
26 Feb

BRIEF-Supernus Pharmaceuticals Q4 Product Sales USD 166.4 Million

Reuters
·
26 Feb

Supernus Pharmaceuticals Q4 Product Sales USD 166.4 Million

THOMSON REUTERS
·
26 Feb

What To Expect From Supernus Pharmaceuticals’s (SUPN) Q4 Earnings

StockStory
·
24 Feb

Supernus Pharmaceuticals Down Nearly 14%, on Pace for Largest Percent Decrease Since November 2020 -- Data Talk

Dow Jones
·
19 Feb

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

Benzinga
·
19 Feb